

**1.6.1 PRESCRIBING INFORMATION (SUMMARY OF PRODUCTS CHARACTERISTICS)**

**1. NAME OF THE FINISHED PHARMACEUTICAL PRODUCT**

Bren-400 (Ibuprofen Tablets BP 400mg)

**1.1 Strength**

Each Film Coated Tablets contains:

Ibuprofen BP 400 mg,

**1.2 Pharmaceutical Form**

Tablets

**2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

**2.1 Qualitative declaration:**

Each Film Coated Tablets contains:

Ibuprofen BP 400 mg

**2.2 Quantitative declaration:****Qualitative declaration:**

Each Film Coated Tablets contains:

Ibuprofen BP 400 mg

**Quantitative declaration:**

Ingredients	Reference	Qty/Tab (mg)	Function
Ibuprofen	BP	400.00	Active Component
Maize Starch	BP	69.00	Binder
Magnesium Stearate	BP	5.00	Lubricant
Purified Talc	BP	3.35	Glidant
Colloidal Silicon Dioxide	BP	5.00	Glidant
Sodium Lauryl Sulphate	BP	5.00	Dissolution enhancer
Sodium Starch Glycollate	BP	8.00	Disintegrant
Hydroxypropyl Methylcellulose	USP/NF	7.65	Film former
Titanium Dioxide	BP	0.35	Opacifier
Colour Erythrosine Lake	IHS	1.00	Colorent
Triacetin	USP	0.65	Plasticiser
Isopropyl Alcohol**	BP	QS	Process solvent
Purified water**	BP	QS	Process solvent
TOTAL		505.00	

BP - British pharmacopoeia

USP /NF– United States Pharmacopoeia/ National Formulary

IHS- In-house specification

\*\* - process solvent does not contribute to weight of tablet

**Module 1– Administrative Information and Product Information**

**2.3 Salts and hydrates**

Pure form present No Salt or hydrate form.

**2.4 Esters and pro-drugs**

Not applicable

**2.5 Oral Powders for solution or suspension**

Not applicable

**2.6 Parenterals excluding powders for reconstitution**

Not applicable

**2.7 Powders for reconstitution prior to parenteral administration**

Not applicable

**2.8 Concentrates**

Not applicable

**2.9 Transdermal patches**

Not applicable

**2.10 Multidose solid or semi-solid products**

Not applicable

**2.11 Biological medicinal products**

Not applicable

### **3. Pharmaceutical form**

Description:

Pink coloured, circular, slightly biconvex, coated tablets.

### **4 Clinical Particulars**

#### **4.1 Therapeutic indications**

Ibuprofen tablets are indicated for the treatment of Pain and inflammation in the rheumatic disease (including juvenile idiopathic arthritis) and other musculoskeletal disorders, Mild to moderate pain including dysmenorrhoea, postoperative analgesia, Migrane, Dental pain, Fever with discomfort and pain in children, Post immunization pyrexia.

#### **4.2 Posology and Method of Administration**

**Posology:**

- Adult and child over 12 years, initially 300-400mg 3-4 times daily; increased if necessary to max 2.4g daily; maintenance dose of 0.6-1.2 g daily may be adequate.
- Pain and fever in children, child 1-4 years, 100 mg 3 times daily (max 30 mg/kg daily in 3-4 divided doses);
- Child 4-7 years, 150 mg 3 times daily (max 30mg/kg daily in 3-4 divided doses);
- Child 7-10 years, 200 mg 3 times daily (up to 30mg/kg daily max 2.4 g in 3-4 divided doses);
- Child 10-12 years, 300 mg 3 times daily (up to 30mg/kg) daily max 2.4g in 3-4 divided doses
- Rheumatic disease in children (including juvenile idiopathic arthritis) Child 3 months -18 years (30-40 mg/kg max 2.4 g daily in 3-4 divided doses.
- Systemic juvenile idiopathic arthritis, up to 60mg/kg max 2.4g daily in 4-6 divided doses.

**Route of administration:** Oral

#### **4.3 Method of Administration:**

Bren-400 should be swallowed with glass of water.

#### **4.4 Contraindications**

- NSAIDs should be used with caution in the elderly, in allergic disorders and in coagulation defects.
- In patients with cardiac impairment, caution is required since NSAIDs may impair renal function. All NSAIDs are contraindicated in severe heart failure. Ibuprofen should be used with caution in uncontrolled hypertension, heart failure, ischemic heart diseases, peripheral artery disease, cerebrovascular disease and when used long-term in patients with risk factors for cardiovascular events. All NSAIDs including ibuprofen is contraindicated.
- In patients with active gastro-intestinal ulceration or bleeding.
- Patients at risk of gastro-intestinal ulceration (including the elderly), who need NSAID treatment should receive gastroprotective treatment.
- Hepatic impairment: NSAIDs should be used with caution in patients with hepatic impairment.
- Renal impairment: NSAIDs should be avoided if possible or used with caution in patients with renal impairment; the lowest effective dose should be used for the shortest possible duration, and renal function should be monitored. Sodium and water retention may occur and renal function may deteriorate, possibly leading to renal failure.

#### **4.5 Special warnings and precautions for use**

##### **WARNINGS**

GI bleeding, ulceration or perforation is higher with increasing NSAID doses, in patients with a history of ulcer, particularly if complicated with a hemorrhage or perforation and in the elderly. These patients should commence treatment on the lowest dose available. Combination therapy with protective agents.

##### **PRECAUTIONS**

Elderly, increased risk of gastrointestinal bleeding and perforation, ulceration who need NSAID treatment should receive gastroprotection treatment.

Caution should be advised in patients receiving concomitant medications which could increase the risk of ulceration or bleeding, such as oral corticosteroids, anticoagulants such as warfarin, selective serotonin-reuptake inhibitors or anti-platelet agents

Respiratory disorder- caution is required if ibuprofen is administered to patients suffering from, or with a previous history of bronchial asthma since NSAIDs have been reported to precipitate bronchospasm in such patients. Associated with increased risk of thrombotic events.

#### **4.6 Interactions with other medicinal products and other forms of interactions**

**Analgesics:** Ibuprofen reduces antiplatelet effect of aspirin.

**Antifungals:** Plasma concentration of ibuprofen increased by fluconazole and voriconazole.

**Cytotoxics:** Ibuprofen reduces excretion of methotrexate (increased risk of toxicity)

**Muscle relaxants:** Ibuprofen reduces excretion of baclofen (increased risk of toxicity)

**Tacrolimus:** Increased risk of nephrotoxicity.

**Module 1– Administrative Information and Product Information**

**4.6 Pregnancy and Lactation**

**Pregnancy:** Ibuprofen should be avoided in pregnancy.

**Lactation:** Ibuprofen should be avoided during breast-feeding.

**4.7 Effects on ability to drive and use machine**

None expected at recommended doses and duration of therapy.

**4.8 Undesirable effects**

Gastro-intestinal disturbances including discomfort, nausea, diarrhoea, and occasionally bleeding and ulceration. Hypersensitivity reactions particularly rashes, angioedema and bronchospasm; Headache, dizziness, nervousness, depression, drowsiness, Insomnia, vertigo, hearing disturbances such as tinnitus, photosensitivity and haematuria, Blood disorders, Fluid retention. Renal failure may be provoked especially in patients with pre-existing renal impairment (rarely, Papillary necrosis or interstitial fibrosis) can lead to renal failure.

**4.9 Overdose and antidote**

The most frequently reported symptoms of overdose include nausea, vomiting, abdominal pain, lethargy and drowsiness. Patients should be treated symptomatically as required. Within one hour of ingestion of a potentially toxic amount, activated charcoal should be considered. Alternatively, in adults, gastric lavage should be considered within one hour of ingestion of a potentially life-threatening overdose. Good urine output should be ensured. Renal and liver function should be closely monitored. Patients should be observed for at least four hours after ingestion of potentially toxic amounts. Frequent or prolonged convulsions should be treated with intravenous diazepam. Other measures may be indicated by the patient's clinical condition.

**Module 1– Administrative Information and Product Information**

**5.0 Pharmacological properties**

**5.1 Pharmacodynamic properties**

**Pharmacotherapeutic group:**

Nonsteroidal anti-inflammatory drug (NSAID) derivative of propionic acid with anti-inflammatory, analgesic, and antipyretic properties.

**ATC code:** MO1AE01.

Ibuprofen is Phenylpropionic acid derivatives. NSAID that has demonstrated its efficacy by non-selective, reversible inhibition of the cyclooxygenase enzyme COX-1 and COX-2.

Furthermore, ibuprofen reversibly inhibits platelet aggregation. Ibuprofen exerts its anti-inflammatory and analgesic effect through inhibition of both COX isoforms. In addition, ibuprofen scavenges HO. radical, NO and ONOO-and can potentiate or inhibit nitric oxide synthase (NOS) isoforms. Ibuprofen may activate anti-nociceptive axis through binding to the cannabinoid receptors and through inhibition of fatty acid amide hydrolase (FAAH) that metabolizes endocannabinoid anandamide.

**5.2 Pharmacokinetic properties**

Ibuprofen is rapidly absorbed following administration and is rapidly distributed throughout the whole body. The excretion is rapid and complete via the kidneys.

Maximum plasma concentrations are reached 45 minutes after ingestion if taken on an empty stomach. When taken with food, peak levels are observed after 1 to 2 hours. These times may vary with different dosage forms.

The half-life of ibuprofen is about 2 hours.

Ibuprofen appears in the breast milk in very low concentrations.

**5.3 Pre-clinical safety data**

There are no pre-clinical data of relevance to the prescriber which are additional to those already included in other sections. Non-clinical data reveal no special hazards for humans based on conventional studies of safety, pharmacology, repeat-dose toxicity or genotoxicity.



**Module 1– Administrative Information and Product Information****6.0 Pharmaceutical Particulars****6.1 List of Excipients**

<b>Sr. No.</b>	<b>Ingredients</b>	<b>Specifications</b>
1.	Maize Starch	BP
2.	Magnesium Stearate	BP
3.	Purified Talc	BP
4.	Colloidal Silicon Dioxide	BP
5.	Sodium Lauryl Sulphate	BP
6.	Sodium Starch Glycollate	BP
7.	Hydroxypropyl Mehtylcellulose	USP/NF
8.	Titanium Dioxide	BP
9.	Colour Erythrosine Lake	IH
10.	Triacetin	USP
11.	Isopropyl Alcohol	BP

**6.2 Incompatibilities:**

None

**6.3 Shelf life**

Proposed shelf life: 36 Months (3 years)

**6.4 Special precautions for storage:**

Store below 30°C. Protect from light.

**6.5 Nature and contents of container**

Alu/Pvc Blister Pack of 10x10 Tablets

OR

HDPE Jar pack of 1000 Tablets

**6.6 Special precautions for disposal and other handling**

None.

**7. Marketing authorization holder.**

**Kopran Limited,**

1076, Parijat House, Dr. E. Moses Road,

Worli, Mumbai - 400 018, India,

Telephone: +91-22-4366 1111

Telefax: +91-22-24950363

E-Mail: mathias@kopran.com

**Manufacturer**

**Kopran Limited,**

Non Pen Plant, Village Savroli

Taluka Khalapur, District Raigad – 410202,

India

Telephone: +91-2192-274200

Telefax: +91-2192-24950363

E-Mail: pdwalekar@kopran.com

**8. Marketing authorization registration number(s).**

Applied for registration

**9. Date of first authorization registration/renewal of the authorization**

Not applicable

**10. Date of revision (if any) of this text.**

Not applicable

**11. DOSIMETRY (IF APPLICABLE)**

Not applicable

**12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS  
(IF APPLICABLE)**

Not applicable